Safe and Effective Use of Nivolumab Monotherapy for Locally Advanced Cutaneous Squamous Cell Carcinoma in a 100-Year-Old Patient.
APA
Inoue S, Hasegawa J, et al. (2026). Safe and Effective Use of Nivolumab Monotherapy for Locally Advanced Cutaneous Squamous Cell Carcinoma in a 100-Year-Old Patient.. The Journal of dermatology, 53(1), e52-e54. https://doi.org/10.1111/1346-8138.70044
MLA
Inoue S, et al.. "Safe and Effective Use of Nivolumab Monotherapy for Locally Advanced Cutaneous Squamous Cell Carcinoma in a 100-Year-Old Patient.." The Journal of dermatology, vol. 53, no. 1, 2026, pp. e52-e54.
PMID
41194311
같은 제1저자의 인용 많은 논문 (4)
- Predictive model for pancreatic fistula in minimally invasive surgery for gastric cancer.
- Urinary biomarkers for immunotherapy response in urothelial carcinoma: current status and future outlook.
- Immunoglobulin G4-related Autoimmune Pancreatitis and Hypopituitarism Following Immune Checkpoint Inhibitor Therapy.
- Response to Letter to the Editor: "In Patients Receiving Pembrolizumab, Adverse Effects on the Pituitary Gland, Heart and Kidneys Must Be Excluded".